Ochsner Health System adopts Magseed® as Standard of Care for Localization of Impalpable Breast Lesions

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Magseed technology guides surgeons during a breast lumpectomy to simplify treatment and improve patient experience

Endomag, the cancer healthcare company, announced today that Ochsner Health System has adopted Magseed® as the standard of care for breast lesion localization, having identified the system as simpler and more effective than alternative techniques. Magseed was chosen as the preferred alternative to wire localization, based on clinician and patient experience, following trials comparing the benefits of this technology with radioactive seed and radar techniques.

Ochsner Health System chose to move away from traditional wire localization, which is known to be restrictive, lengthy and an uncomfortable procedure for patients. Wire systems must be conducted on the same day as surgery and can result in delays, infection, and a higher risk of cancerous tissue being left behind.

Having explored alternative techniques, including radioactive seed localization (RSL) and radar localization, Ochsner Health System, which provides cancer care to around 15,000 patients per year, found Magseed to provide significant advantages for both surgeon and patient, and has chosen the technology as the Health System’s preferred localization technique for breast lesions.

While RSL provides an alternative to wire techniques and can be conducted several days ahead of surgery, setting up a program can be difficult to coordinate across multiple hospital departments. The procedure also places a heavy burden on clinicians who need to closely track the seeds to ensure radio-labeled material is recovered from the breast specimen.

Radar localization, an alternative non-radioactive technique, uses micro-impulse radar to detect a reflector that is placed at the tumor site up to 30 days ahead of surgery. However, the reflectors are quite large in comparison with Magseed and can be damaged during placement within the lesion. Once inside the breast tissue, the reflector can be difficult to locate from all orientations and a second scanner is required to confirm that it is still working.

“Radar localization was eventually dismissed due to its slower, more cumbersome scanning that made it hard to locate the reflector. By contrast the Sentimag probe was much faster and its immediate feedback made it easier to scan the breast and locate Magseed,” cites Dr Aimee Mackey, Breast Surgeon, Ochsner Health System.

Magseed was identified as the most patient-centered localization technique available, offering the precision of radioseeds without the safety and regulatory concerns associated with radioactive exposure. Magseed cannot be damaged during placement. The clarity of imaging provided by the system enables confident and efficient placement within the breast lesion, and ease of location during surgery. As a result, this technique can be performed rapidly, allowing more patients to benefit from treatment.

Dr Dana Smetherman, Section Head, Breast Imaging, Ochsner Health System, added,“Overall we found that Magseed tackles most of the technical and safety issues associated with wire localization, radioactive seeds, and radar localization. We believe that this is the best technology for our patients. Once they become aware that this technology is available to them, we’re certain that Ochsner Health System will be their preferred treatment provider.”

Dr Aimee Mackey concluded: “We are very pleased to have adopted this robust and accurate technology that will enable our department to effectively treat a greater number of patients. Magseed removes many of the complications associated with traditional wire and more fragile localization systems, and is easier to deploy and locate. This advanced, non-radioactive technology provides reassurance for clinicians and a more comfortable experience for patients.”



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles